Zpráva o průběhu klinického hodnocení „RASmiR" Racionální výběr Anti-EGFR terapie v první linii léčby pacientů s metastazujícím kolorektálním karcinomem wild-type KRAS / NRAS na základě použití molekulárního prediktoru miR-31-5p

Title in English Clinical Trial Interim Report: „RASmiR" Rational Anti-EGFR therapy Selection for the first-line treatment of patients with metastatic KRAS/NRAS wild type colorectal cancer based on the use of molecular predictor miR-31-5p


Year of publication 2020
MU Faculty or unit

Faculty of Medicine

Attached files
Description Clinical Trial RASmiR EudraCT number 2018-001210-15 The clinical trial interim report describes the course and current status of the clinical trial (KH) in a defined period. It includes information on document updates, changes in KH centers and examiners, an overview of previously included/completed subjects of evaluation, and detected protocol violations. It also contains information on investigational medicine (reporting serious adverse events, suspicions of serious (unexpected) adverse events, or new findings in relation to safety and efficacy), new measures taken, and audits performed.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.

More info